Vanda Pharmaceuticals appoints chief commercial officer
Bob Repella joins US biopharmaceutical firm
Repella has more than 25 years of experience in the biotech/pharmaceutical industry, including senior-level leadership roles in global marketing, sales, new product development and commercial operations.
Prior to joining Vanda, he was senior vice president of Pharmaceutical Operations for the Americas at Cephalon.
Before this, Repella was executive vice president and general manager of the Biopharma Business Unit for Wyeth Pharmaceuticals.
Earlier in his career, Repella held positions with Johnson & Johnson's McNeil Pharmaceutical Division, Merck & Co and Eli Lilly.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
![Beyond the Vacuum Pump: Is your Vacuum System costing more than you think?]()
Beyond the Vacuum Pump: Is your Vacuum System costing more than you think?
Many facilities continue to rely on oil-lubricated vacuum pumps that were installed years ago. The question is no longer whether these pumps work. The question is whether they remain the most efficient solution for today's operational, environmental and productivity requirements
Manufacturing
![Why CAPA keeps failing and what strong organisations do differently]()
Why CAPA keeps failing and what strong organisations do differently
This white paper examines why CAPA systems often close records without preventing recurrence, tracing breakdowns to investigation quality, risk reasoning, and organisational behaviour rather than procedural gaps. It outlines what differentiates compliant CAPA programmes from those that consistently reduce repeat findings and inspection risk
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
![Beyond FAT and SAT: a practical framework to qualify multivendor pharmaceutical manufacturing lines (part II)]()
Beyond FAT and SAT: a practical framework to qualify multivendor pharmaceutical manufacturing lines (part II)
How a centralised qualification matrix reconciles vendor documentation, integrates risk-based verification and connects commissioning findings with deviation, CAPA and audit-ready evidence
